These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26204325)

  • 1. Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.
    Orleth A; Mamot C; Rochlitz C; Ritschard R; Alitalo K; Christofori G; Wicki A
    J Drug Target; 2016; 24(1):80-9. PubMed ID: 26204325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3.
    Jimenez X; Lu D; Brennan L; Persaud K; Liu M; Miao H; Witte L; Zhu Z
    Mol Cancer Ther; 2005 Mar; 4(3):427-34. PubMed ID: 15767551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
    Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
    J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGFR3 does not sustain retinal angiogenesis without VEGFR2.
    Zarkada G; Heinolainen K; Makinen T; Kubota Y; Alitalo K
    Proc Natl Acad Sci U S A; 2015 Jan; 112(3):761-6. PubMed ID: 25561555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
    Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
    Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
    J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular controls of lymphatic VEGFR3 signaling.
    Deng Y; Zhang X; Simons M
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific anti-glioma angiogenesis immune response induced by attenuated Salmonella typhimurium vaccine expressing vascular endothelial growth factor receptor-2].
    Feng KK; Zhao HY; Qiu H; Chen J
    Ai Zheng; 2005 May; 24(5):548-53. PubMed ID: 15890095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
    Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
    J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
    Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth.
    Xuan ZX; Li LN; Zhang Q; Xu CW; Yang DX; Yuan Y; An YH; Wang SS; Li XW; Yuan SJ
    Int J Oncol; 2014 Dec; 45(6):2411-20. PubMed ID: 25269419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.
    Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H
    J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes.
    Dicheva BM; ten Hagen TL; Schipper D; Seynhaeve AL; van Rhoon GC; Eggermont AM; Koning GA
    J Control Release; 2014 Dec; 195():37-48. PubMed ID: 25176578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.